Skip to main content

Advertisement

SpringerLink
Log in

GISTogram: a graphic presentation of the growing GIST complexity

  • Review and Perspectives
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. They have represented a paradigm of molecular-targeted therapies for solid tumors since the discovery of KIT mutations and KIT expression in GIST in 1998, which opened the way to the use of imatinib, a tyrosine kinase inhibitor able to inhibit the growth of cells expressing KIT-mutant isoforms. Since then, accumulating evidence revealed the rather heterogeneous nature of GIST, implying possible different diagnostic and therapeutic approaches for each specific case, leading to the development of drugs alternative to imatinib. In this brief commentary, we graphically represent the historical growing of genotype and phenotype evidence on GIST since 1998 in its increasing complexity by building up a graph, which we have called “GISTogram”, that visually conveys most of GIST-characterizing features and the probability for each of them, either alone or in combination, to be observed in a single GIST case.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  PubMed  CAS  Google Scholar 

  2. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728–734

    PubMed  CAS  Google Scholar 

  3. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269

    PubMed  CAS  Google Scholar 

  4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056

    Article  PubMed  CAS  Google Scholar 

  5. Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, Doucet L, Hostein I, Landi B, Buisine MP, Neuville A, Bouché O, Cervera P, Pretet JL, Tisserand J, Gauthier A, Le Cesne A, Sabourin JC, Scoazec JY, Bonvalot S, Corless CL, Heinrich MC, Blay JY, Aegerter P (2012) Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 29:1765–1772

    Article  PubMed  CAS  Google Scholar 

  6. Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M (2007) Mutations in gastrointestinal stromal tumors—a population-based study from Northern Norway. APMIS 115:289–298

    Article  PubMed  CAS  Google Scholar 

  7. Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11:865–878

    PubMed  CAS  Google Scholar 

  8. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710

    Article  PubMed  CAS  Google Scholar 

  9. Liegl-Atzwanger B, Fletcher JA, Fletcher CD (2010) Gastrointestinal stromal tumors. Virchows Arch 456:111–127

    Article  PubMed  Google Scholar 

  10. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutational status. Am J Pathol 165:107–113

    Article  PubMed  CAS  Google Scholar 

  11. Miettinen M, Lasota J (2011) Histopathology of gastrointestinal stromal tumor. J Surg Oncol 104:865–873

    Article  PubMed  CAS  Google Scholar 

  12. Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, Sartor C, Hogendoorn PC, Sciot R, Van Glabbeke M, Verweij J, Blay JY, Hohenberger P, Flanagan A, Dei Tos AP (2010) DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 57:259–270

    Article  PubMed  Google Scholar 

  13. Yamamoto H, Kojima A, Nagata S, Tomita Y, Takahashi S, Oda Y (2011) KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases. Am J Surg Pathol 35:1287–1295

    Article  PubMed  Google Scholar 

  14. Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pauwels P, De Wever I, Vermeesch JR, de Raedt T, De Paepe A, Speleman F, van Oosterom A, Messiaen L, Legius E (2006) Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 15:1015–1023

    Article  PubMed  CAS  Google Scholar 

  15. Fuller CE, Williams GT (1991) Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology 19:1–11

    Article  PubMed  CAS  Google Scholar 

  16. Kinoshita K, Hirota S, Isozaki K, Ohashi A, Nishida T, Kitamura Y, Shinomura Y, Matsuzawa Y (2004) Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 202:80–85

    Article  PubMed  CAS  Google Scholar 

  17. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, Gronchi A, Casali PG, Dei Tos AP (2011) Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 35:1646–1656

    Article  PubMed  Google Scholar 

  18. Agaimy A, Hartmann A (2010) Hereditäre und nichtereditäre syndromale gastrointestinale Stromaltumoren. Pathologe 31:430–437

    Article  PubMed  CAS  Google Scholar 

  19. Lasota J, Miettinen M (2006) KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 23:91–102

    Article  PubMed  Google Scholar 

  20. Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J (2011) Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 35:1712–1721

    Article  PubMed  Google Scholar 

  21. Chou A, Chen J, Clarkson A, Samra JS, Clifton-Bligh RJ, Hugh TJ, Gill AJ (2012) Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression. Modern Pathol 25:1307–1313

    Article  CAS  Google Scholar 

  22. Pappo AS, Janeway K, Laquaglia M, Kim SY (2011) Special considerations in pediatric gastrointestinal tumors. J Surg Oncol 104:928–932

    Article  PubMed  Google Scholar 

  23. McWhinney SR, Pasini B, Stratakis CA, International Carney Triad and Carney–Stratakis Syndrome Consortium (2007) Familial gastrointestinal stromal tumors and germ-line mutations. N Engl J Med 357:1054–1056

    Article  PubMed  CAS  Google Scholar 

  24. Pantaleo MA, Astolfi A, Indio V, Moore R, Thiessen N, Heinrich MC, Gnocchi C, Santini D, Catena F, Formica S, Martelli PL, Casadio R, Pession A, Biasco G (2011) SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst 103:983–987

    Article  PubMed  CAS  Google Scholar 

  25. Celestino R, Lima J, Faustino A, Máximo V, Gouveia A, Vinagre J, Soares P, Lopes JM (2012) A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney–Stratakis dyad. Fam Cancer 11:189–194

    Article  PubMed  Google Scholar 

  26. Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, Hornick JL, Pediatric NIH, Wild-Type GIST, Clinic O'SM, de Krijger RR, Dinjens WN, Demetri GD, Antonescu CR, Fletcher JA, Helman L, Stratakis CA (2011) Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 108:314–318

    Article  PubMed  CAS  Google Scholar 

  27. Doyle LA, Nelson D, Heinrich MC, Corless CL, Hornick JL (2012) Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology 61:801–809

    Article  PubMed  Google Scholar 

  28. Lasota J, Wang Z, Kim SY, Helman L, Miettinen M (2013) Expression of the receptor for type I insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol 37:114–119

    Article  PubMed  Google Scholar 

  29. Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47:853–859

    Article  PubMed  CAS  Google Scholar 

  30. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769–1776

    Article  PubMed  CAS  Google Scholar 

  31. Daniels M, Lurkin I, Pauli R, Erbstösser E, Hildebrandt U, Hellwig K, Zschille U, Lüders P, Krüger G, Knolle J, Stengel B, Prall F, Hertel K, Lobeck H, Popp B, Theissig F, Wünsch P, Zwarthoff E, Agaimy A, Schneider-Stock R (2011) Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 312:43–54

    Article  PubMed  CAS  Google Scholar 

  32. Agaimy A, Märkl B, Arnholdt H, Wünsch PH, Terracciano LM, Dirnhofer S, Hartmann A, Tornillo L, Bihl MP (2009) Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs. Virchows Arch 455:101–108

    Article  PubMed  CAS  Google Scholar 

  33. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, Bringuier PP, Scoazec JY, Coindre JM (2010) BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 133:141–148

    Article  PubMed  CAS  Google Scholar 

  34. Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R (2013) BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 4:310–315

    PubMed  CAS  Google Scholar 

  35. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118:4014–4023

    Article  PubMed  CAS  Google Scholar 

  36. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB (2012) BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39:821–825

    Article  PubMed  Google Scholar 

  37. Blair SL, Al-Refaie WB, Wang-Rodriguez J, Behling C, Ali MW, Moossa AR (2005) Gastrointestinal stromal tumors express ras oncogene: a potential role for diagnosis and treatment. Arch Surg 140:543–547

    Article  PubMed  Google Scholar 

  38. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118:4014–4023

    Article  PubMed  CAS  Google Scholar 

  39. Sakamoto A, Oda Y, Adachi T, Tamiya S, Matsuda S, Tanaka K, Iwamoto Y, Tsuneyoshi M (2001) H-ras oncogene mutation in dedifferentiated liposarcoma. Polymerase chain reaction-restriction fragment length polymorphism analysis. Am J Clin Pathol 115:235–242

    Article  PubMed  CAS  Google Scholar 

  40. Sakamoto A, Oda Y, Adachi T, Oshiro Y, Tamiya S, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M (2001) H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis. Mod Pathol 14:343–349

    Article  PubMed  CAS  Google Scholar 

  41. Weihrauch M, Bader M, Lehnert G, Koch B, Wittekind C, Wrbitzky R, Tannapfel A (2002) Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride. Environ Mol Mutagen 40:36–40

    Article  PubMed  CAS  Google Scholar 

  42. Wong NACS, Deans ZC, Ramsden SC (2012) The UK NEQAS for molecular genetic scheme for gastrointestinal stromal tumour: findings and recommendations following four rounds of circulation. J Clin Pathol 65:786–790

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was in part supported by line D1 grants 2010 and 2011 to RR and GR.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pathology, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168, Roma, Italy

    Riccardo Ricci & Guido Rindi

  2. Department of Pathology, Treviso Regional Hospital, Piazza Ospedale 1, 31100, Treviso, Italy

    Angelo Paolo Dei Tos

Authors
  1. Riccardo Ricci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angelo Paolo Dei Tos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guido Rindi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Riccardo Ricci.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

JPEG 7 kb

High-resolution image

TIFF 10,689 kb

ESM 2

JPEG 12 kb

High-resolution image

TIFF 10,689 kb

ESM 3

JPEG 84 kb

High-resolution image

TIFF 10,689 kb

ESM 4

JPEG 87 kb

High-resolution image

TIFF 10,689 kb

ESM 5

JPEG 102 kb

High-resolution image

TIFF 10,689 kb

ESM 6

JPEG 104 kb

High-resolution image

TIFF 10,690 kb

ESM 7

JPEG 107 kb

High-resolution image

TIFF 10,690 kb

ESM 8

JPEG 108 kb

High-resolution image

TIFF 10,690 kb

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ricci, R., Dei Tos, A.P. & Rindi, G. GISTogram: a graphic presentation of the growing GIST complexity. Virchows Arch 463, 481–487 (2013). https://doi.org/10.1007/s00428-013-1467-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-013-1467-4

Keywords

Search

Navigation